M&A Deal Summary

Merz Pharma KGaA Acquires BioForm Medical

On January 4, 2010, Merz Pharma KGaA acquired medical products company BioForm Medical from EW Healthcare Partners for 253M USD

Acquisition Highlights
  • This is Merz Pharma KGaA’s 1st transaction in the Medical Products sector.
  • This is Merz Pharma KGaA’s largest (disclosed) transaction.
  • This is Merz Pharma KGaA’s 1st transaction in the United States.
  • This is Merz Pharma KGaA’s 1st transaction in California.

M&A Deal Summary
Date 2010-01-04
Target BioForm Medical
Sector Medical Products
Buyer(s) Merz Pharma KGaA
Sellers(s) EW Healthcare Partners
Deal Type Add-on Acquisition
Deal Value 253M USD
Advisor(s) J.P. Morgan Securities (Financial)
Dewey & LeBoeuf LLP
Ropes & Gray (Legal)

Target

BioForm Medical

San Mateo, California, United States
Bioform Medical is a medical device company introducing a family of proprietary, injectable implant products used in minimally invasive soft tissue augmentation procedures. The lead product, Radiesse, will be used for aesthetic/cosmetic indications.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Merz Pharma KGaA

Frankfurt am Main, Germany
Category Company
Sector Life Science
Revenue 980M USD (2012)
DESCRIPTION

Merz Pharma GmbH & Co. KGaA combines the activities of its three subsidiaries, namely Merz Pharmaceuticals, Merz Consumer Care, and Merz Dental.

DEAL STATS #
Overall 1 of 6
Sector (Medical Products) 1 of 2
Type (Add-on Acquisition) 1 of 5
State (California) 1 of 2
Country (United States) 1 of 4
Year (2010) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-07-19 Lasya - Intellectual Property Assets

Carrboro, North Carolina, United States

Lasya, Inc. - Intellectual Property Assets includes both U.S. and international patent filings of deoxyArbutin.

Buy -

Seller(S) 1

SELLER

EW Healthcare Partners

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Founded 1985
PE ASSETS 3.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Essex Woodlands Health Ventures is a growth equity and venture capital specialist investment firm focused on opportunities across the healthcare sector. Specific areas of interest include biotechnology, pharmaceuticals, medical devices, and healthcare services/IT. Historically, Essex invested primarily in early and later-stage situations; however, today the firm also makes growth capital investments between $20 - $60 million in companies valued between $50 - $250 million, as well as private investments in public entities (PIPEs). Essex Woodlands was formed in 1985 and offices in Palo Alto, California; New York City; Houston, Texas; Shanghai and London.

DEAL STATS #
Overall 16 of 53
Sector (Medical Products) 7 of 24
Type (Add-on Acquisition) 9 of 34
State (California) 6 of 17
Country (United States) 14 of 46
Year (2010) 1 of 7
Size (of disclosed) 10 of 22
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2009-12-15 Molecular Partners

Schlieren, Switzerland

Molecular Partners is a clinical-stage biotech company developing DARP in therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. Molecular Partners was founded in 2004 and is headquartered in Schlieren, Switzerland.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2010-01-06 InSound Medical

Newark, California, United States

InSound Medical is a developer and manufacturer of hearing devices.

Sell $75M
Mergr

Product

Company

Legal